About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

RECRUITINGNCT07605572

Impact of GLP-1 Receptor Agonists on Dry Eye Disease in Patients With Type 2 Diabetes Mellitus and Obesity

Diabetes mellitus (DM), prediabetes, and obesity are emerging as major global public health problems, with their epidemic spread continuously increasing over the past decades. The occurrence of diabet...

Lead sponsor: Attikon Hospital•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Vaia Lambadiari, MD, PhD

CONTACT

(0030)2105838000 vlambadiari@gmail.com

Sponsors

Lead Sponsor

Attikon Hospital

This prospective cohort study aims to shed a light to the effects of GLP-1 RAs on Dry Eye Disease in Patients with Type 2 Diabetes Mellitus and Obesity.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Age ≥18 years.
•2. Patients who have not previously received GLP-1 receptor agonists (GLP-1 RAs).
•3. Patients able to provide informed consent for participation in the study.

Exclusion Criteria

•1. Pregnant or breastfeeding patients.
•2. History of multiple severe hypoglycemic episodes within the past two years.
•3. Active intraocular inflammation in either eye, such as infectious conjunctivitis, keratitis, scleritis, endophthalmitis, or autoimmune uveitis.
•4. Patients who have undergone cataract surgery or vitrectomy within the past 6 months.
•5. History of ketoacidosis or metabolic acidosis.
•6. History of corneal transplantation.

Related studies

Serum Cholinesterases, Paraoxonase, and Cardiovascular Risk After Intravitreal Bevacizumab

NCT07550777 · Diabete Mellitus, Retina Vein Occlusion, and more

Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass

NCT07272837 · Type 2 Diabetes, Obesity, and more

RECRUITINGPhase 4

A Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears: the FOCUS Study

NCT07463950 · Dry Eye Disease (DED)

"Erectile Function After PCI in MI and Non-MI Patients"

NCT07444697 · Erectile Disfunction, Coronary Artery Disease (CAD), and more

Assessing the Effectiveness of Large Language Model (LLM)-Enabled Nurse Treatment Planning in 2 Indian Districts

NCT07432893 · Hypertension, Diabete Mellitus, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: June 2, 2026Terms

Trial snapshot

StatusRECRUITING

Phase—

Enrollment100

Start dateMar 2026

Last updatedJun 2, 2026

Condition

Dry Eye Disease (DED)Diabete Mellitus GLP-1 Ocular Surface Diabetes Type 2+1 more

Locations shown

2nd Department of Internal Medicine, Research Institute and Diabetes Center, National and Kapodistrian University of Athens, Athens, GRC.

Athens

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 2, 2026Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions